Citations

Clear

6273 citation(s) found for "To, Andrew".

Survival benefit associated with liver transplantation for hepatocellular carcinoma based on tumor burden scores at listing
Liu, Hao , Lee, Hang , Shi, Liuhua , Wang, Xixi , Powers, Colin , Li, Xingjie , Alberola, Ramon Bataller, Behari, Jaideep , Duarte‐Rojo, Andrés , Hughes, Dempsey L. , Malik, Shahid M. , Jonassaint, Naudia , Tohme, Samer , Gunabushanam, Vikraman , Tevar, Amit D. , Cruz, Ruy J. , Dharmayan, Stalin, Ayloo, Subhashini, Humar, Abhinav , Liu, Hao , Duarte-Rojo, Andres , Zhang, Wei , Di, Mengyang , Wang, Xixi, Zhang, Xingyu , Sethi, Vrishketan , Xiao, Yao , Crane, Andrew, Kaltenmeier, Christof , Geller, David A. , Hughes, Christopher L. , Molinari, Michele

Mayo Clinic

Hepatology Communications | January 7, 2025 | Volume: 9 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000619 | PMID 39774957 Get It

Introduction: Liver transplantation (LT) provides significant survival benefits to patients with unresectable HCC. In the United States, organ allocation policies for HCCs within the United Network for Organ Sharing criteria do not prioritize patients based on their differences in oncological characteristics. This study assessed whether transplant-associated survival benefits (TASBs) vary among patients with different tumor burden scores (TBS) measured at the time of listing. Methods: We analyzed data from adults applying for HCC MELD exception points between 2002 and 2019, with follow-up until December 2023, using the Scientific Registry of Transplant Recipients. TBS was determined based on the largest tumor diameter and number of HCCs. Patients were categorized into low (≤3), intermediate (3.1–5), and high (>5) TBS groups. TASB was measured as the difference in 5-year survival with and without LT. Results: This study included 36,634 LT candidates. High-TBS patients had higher waitlist dropout rates and marginally lower post-transplant survival, resulting in a significantly greater TASB. The 5-year TASB for the low, intermediate, and high TBS groups were 15.7, 22.1, and 25.0 months, respectively. The adjusted survival benefit expressed in 5-year survival differences was 21.9%, 34.5%, and 39.4% in the low, intermediate, and high TBS groups, respectively ( p <0.001). Conclusions: Higher TBS during listing correlates with greater LT benefits for patients with unresectable HCC within UNOS criteria. We conclude that organ allocation policies in the United States should prioritize patients with high TBS due to their increased risk of dropout and comparable post-transplant survival when compared to patients with less advanced tumors.
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease
Hong, Simon , Dalal, Rahul S. , Kuhn, Kristine A. , Stahly, Andrew , Scott, Frank I. , Click, Benjamin , Way, Anna, Malik, Fardina , Davis, John M. , Shmais, Manar , Raffals, Laura E., Silfen, Alexa , Dharia, Ishaan , Bhattacharya, Ashish K. , Moghaddam, Bahar, Mains, Trayton, Kurland, Jayde E., Hong, Simon J , Click, Benjamin H , Rubin, David T , Bhattacharya, Abhik , Ermann, Joerg , Jan, Reem , Davis, John M , Silfen, Alexa , Kuhn, Kristine A , Scott, Frank I , Way, Anna, Raffals, Laura E. , Rubin, David T. , Patel, Sheena , Weisman, Michael H. , Ermann, Joerg

Mayo Clinic

American Journal of Gastroenterology | January 6, 2025 | Volume: 120 | Issue: 10 | Pages: 2330-2338

10.14309/ajg.0000000000003292 | PMID 39760386 Get It

INTRODUCTION: Spondyloarthritis (SpA), the most common extraintestinal manifestation of inflammatory bowel disease (IBD), is reported in up to 39% of patients with IBD. Despite this high prevalence, risk factors of developing SpA in patients with IBD are not well described. In this study, we aimed to determine the factors associated with SpA symptoms and their prevalence in an IBD cohort. METHODS: Two validated screening questionnaires for the detection of SpA in IBD (DETAIL = DETection of Arthritis in Inflammatory boweL diseases, IBIS-Q = IBD Identification of Spondyloarthritis Questionnaire) were administered to patients with IBD without a prior diagnosis of SpA in 6 US academic medical centers. Demographic data, IBD characteristics, and medication history were recorded. RESULTS: Screening questionnaires were completed by 588 patients (220 ulcerative colitis, 349 Crohn's disease, and 19 IBD-unclassified), with a median age of 40 years (interquartile range 30–53) and median disease duration of 12 years (interquartile range 6–22). The number of positive screens was 130 (22%) for DETAIL, 196 (33%) for IBIS-Q, and 204 (35%) for either DETAIL or IBIS-Q. Age, female sex, history of smoking, prior bowel surgery, and history of any biologic or targeted small molecule exposure were associated with a positive screen on univariate analysis. After multivariate analysis, female sex (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.41–2.93), older age (OR 1.02, 95% CI 1.01–1.04), history of smoking (OR 1.67, 95% CI 1.04–2.69), and history of any biologic or targeted small molecule exposure (OR 2.27, 95% CI 1.34–3.84) were independently associated with positive screens. Higher number of biologic exposures was associated with higher risk of positive screens, with the highest risk seen with 3 or more exposures (OR 3.25, 95% CI 1.75–6.03). DISCUSSION: A substantial number of patients with IBD screen positive for SpA symptoms, indicating a potentially high burden of undiagnosed illness. Factors associated with SpA symptoms include older age, female sex, and more severe disease (based on increased number of advanced therapies or prior surgery), whereas IBD phenotype does not independently increase the risk of a positive SpA screen. Further studies are needed to confirm these findings and better characterize SpA in IBD.
Solving climate change requires changing our food systems
Feigin, Svetlana , Wiebers, David O. , Blumstein, Daniel T. , Knight, Andrew , Eshel, Gidon , Lueddeke, George R., Kopnina, Helen , Brainin, Michael, Alexander, Shelley M., Merskin, Debra , Kleef, Gerben A. van , Freeman, Carrie Packwood , Feigin, Valery L. , Morand, Sergé , Lee, Kelley , Shackelford, Todd K. , Marcum, James A. , Skerratt, Lee Francis , Whitfort, Amanda S. , Winkler, Andrea Sylvia

Mayo Clinic

Oxford Open Climate Change | January 3, 2025 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/oxfclm/kgae024 Get It

Abstract Humanity is facing an important existential threat—irreversible climate change caused by human activity. Until recently, most of the proposals to address climate change have downplayed or ignored the adverse impact of food systems, especially intensive animal agriculture. This is in spite of the fact that up to a third of global greenhouse gas production to date can be attributed to animal agriculture. Recent developments at COP28 have signaled that the tide is turning, however, and that food systems are becoming part of global discussions on climate change solutions. The pressing nature of irreversible climate change requires rethinking our food systems. To solve the climate change crisis, we propose transitioning to a predominantly plant-based diet, and phasing out intensive animal agriculture as diets shift, without increasing pastoral farming. We suggest that such transformations in global food systems can be accomplished largely through education and large-scale public information campaigns, removal of subsidies, taxation to account for externalized costs of animal agriculture, improved labelling of products, and various investment/divestment drivers. Better metrics and industry benchmarks involving food and agriculture-specific performance indicators that reflect food system sustainability will be important. Increased global awareness of these issues and a change in mindset (which will drive political will) also are needed. Our current trajectory is untenable, and we must begin to turn the ship now towards sustainable food systems and diets.
Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG)
Gong, Li , Klein, Clarissa , Caudle, Kelly E. , Moyer, Ann M. , Klein, Teri E. , (PGxWG), ClinGen Pharmacogenomics Working Group, Ashcraft, Kristine , Bernhardt, Brooke, Blaxwell, Burns C, Bly, Zo, Cody, Neal, Tredici, Andria L. Del , Gregornik, David , Hart, Jennifer, Hoffman, James M. , Landrum, Melissa , Langlais, Kristofor K., Lee, M T M, Li, Rongling, McLeod, Howard L. , Monte, Andrew A. , Naik, Hetanshi , Obeng, Aniwaa Owusu , Ramos, Erin M. , Ren, Zhaoxia , Ritchie, Marylyn D. , Scherer, Steven E. , Shaaban, Sherin, Swen, Jesse J. , McIntyre, Joanne, Merritt, Keren, Wright, Matt W. , Klein, Teri E , Scott, Stuart A. , Whirl‐Carrillo, Michelle , (PGxWG), ClinGen Pharmacogenomics Working Group, Aminkeng, Folefac , Amr, Sami S , Cipriani, Amber , Dandara, Collet , Empey, Philip E. , Fieg, Elizabeth L. , Gaedigk, Andrea , Harrison, Steven M. , Hunter, Jessica Ezzell , Iwuchukwu, Otito Frances , Malheiro, Adriana , Morales, Joannella , Oni‐Orisan, Akinyemi , Rogers, Sara , Wagner, Alex H. , Woodahl, Erica L , McIntyre, Joanne, Merritt, Keren

Mayo Clinic

Clinical Chemistry | January 3, 2025 | Volume: 71 | Issue: 1 | Pages: 36-44

10.1093/clinchem/hvae181 | PMID 39749515 Get It

Abstract Pharmacogenomics (PGx) is focused on the relationship between an individual's genetic makeup and their response to medications, with the overarching aim of guiding prescribing decisions to improve drug efficacy and reduce adverse events. The PGx and genomic medicine communities have worked independently for over 2 decades, developing separate standards and terminology, making implementation of PGx across all areas of genomic medicine difficult. To address this issue, the Clinical Genome Resource (ClinGen) Pharmacogenomics Working Group (PGxWG) was established by the National Institutes of Health (NIH)-funded ClinGen to initially create frameworks for evaluating gene–drug response clinical validity and actionability aligned with the ClinGen frameworks for evaluating monogenic gene–disease relationships, and a framework for classifying germline PGx variants similar to the American College of Medical Genetics (ACMG) and Association of Molecular Pathology (AMP) system for interpretation of disease-causing variants. These frameworks will leverage decades of work from well-established PGx resources facilitating buy-in among PGx stakeholders. In this report, we describe the background and major activities of the ClinGen PGxWG, and how this initiative will facilitate the critical inclusion of PGx into the larger context of genomic medicine.
Innovations in Short-Read Sequencing Technologies and Their Applications to Clinical Genomics
Blommel, Joseph H. , Hughes, Andrew , Spencer, David H. , Thompson, Joseph A., Schroeder, Molly C. , Blommel, Joseph H , Hughes, Andrew E O , Spencer, David , Schroeder, Molly C , Polonis, Katarzyna

Mayo Clinic

Clinical Chemistry | January 3, 2025 | Volume: 71 | Issue: 1 | Pages: 97-108

10.1093/clinchem/hvae173 | PMID 39749506 Get It

Abstract Background Massively parallel sequencing (MPS) of nucleic acids has been a transformative technology for basic and applied genomic science, increasing efficiencies and decreasing costs to enable studies of unprecedented scope and impact. In clinical settings, these technological and scientific advances have led to the development of tests that are increasingly fast, comprehensive, and more frequently employed. Practitioners of genomic medicine have applied these tools across clinical settings, including diagnosis of inherited disorders and cancers and infectious disease detection and surveillance. In recent years, the commercial marketplace for MPS sequencers and reagents has been dominated by a few companies. The growing demand for sequencing has led to the recent emergence of several new sequencing platforms with techniques that may provide alternatives or improvements to existing workflows or allow the adoption of sequencing workflows in new settings. Clinical genomics laboratories will evaluate these platforms from a unique perspective, focusing on how technological advancements can improve patient care. Content This review describes short-read sequencing platforms provided by Illumina, Element Biosciences, MGI, PacBio, Singular Genomics, Thermo Fisher Scientific, and Ultima Genomics. This review discusses their innovative approaches, principles, workflows, and applications. Summary This review aims to inform laboratory geneticists, clinicians, and researchers about emerging short-read technologies and their applications in clinical genomics. By highlighting their principles and potential contributions, we aim to assist laboratories in selecting suitable solutions for their sequencing needs considering key factors such as applications, throughput, and integration with existing laboratory workflows.
Preserved transcriptional networks in immune signaling pathways associated with chronic disease identified in Alzheimer’s disease and Parkinson’s disease, cross‐tissue analysis
Strickland, Samantha L. , Tsai, Wei, Chen, Xuan , Cherukuri, Yesesri , Allen, Mariet , Quicksall, Zachary , Wang, Xue , Carrasquillo, Minerva M. , Nho, Kwangsik, Petersen, Ronald C., Reddy, Joseph S. , Ertekin‐Taner, Nilüfer , Kantarci, Kejal , Carrasquillo, Minerva M. , Saykin, Andrew J. , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.092349 Get It

AbstractBackgroundSystemic inflammation plays a pivotal role in many chronic diseases including Alzheimer’s disease (AD). Assessing the composition of immune pathways in neurodegenerative diseases can contribute to precision medicine. Using publicly available transcriptomic data, we sought to elucidate transcriptional networks pertinent to inflammatory pathways across brain regions and peripheral blood in AD/mild cognitive impairment (MCI) and peripheral blood in Parkinson’s disease (PD).MethodFor the AD/MCI vs. control dataset, we analyzed bulk‐RNAseq collected from 6 brain regions of donors from ROSMAP, Mayo Clinic, and Mount Sinai School of Medicine (MSSM) brain banks available from the AMP‐AD consortium. Ante‐mortem, blood RNAseq expression data was retrieved from the AMP‐AD Emory Vascular cohort and Mayo Clinic Study of Aging (MCSA). We also collected blood‐derived microarray expression data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). For the PD vs Control dataset, blood‐derived bulk‐RNAseq from the PDBP and PPMI cohorts were available through the AMP‐PD consortium. Following quality control, normalization, and residual generation to account for biological and technical variables, co‐expression network modules and their enriched pathways were identified using WGCNA within each dataset. Module/trait correlation tests for aging and diagnosis (cases [AD/MCI or PD] vs control) phenotypes were evaluated. Gene Ontology enrichment analyses were executed to identify enriched pathways and brain or blood cell types within the modules. Modules were tested for preservation across cohorts.ResultWe identified conserved immune signatures across brain regions and cohorts. Modules involved in immune response were preserved across all cohorts. Blood consensus modules involved in immune response were preserved in the brain and vice versa. Some immune modules were associated with AD/MCI, PD, and/or aging. Brain immune modules are significantly associated with aging and/or AD. Significant correlations (q<0.05) with PD diagnosis were present. In the MCSA and Emory vascular cohorts, there were no significant (q<0.05) associations between modules and diagnosis, while in ADNI there were nominal (p<0.05) associations.ConclusionPreserved transcriptional immune networks were identified across blood and brain and across two neurodegenerative diseases. Expanding gene co‐expression network analyses to other diseases and integrating additional omics measures and phenotypes can further strengthen these findings to unravel the immune signatures across complex diseases.
Multi‐omics profiling of Alzheimer’s disease in multi‐ethnic populations
Reddy, Joseph S. , Allen, Mariet , Poehlman, William L. , Wang, Yanling , Johnson, Ryan , Ho, Charlotte C.G. , Linden, Abby Vander , Quicksall, Zachary , Chen, Xianfeng , Baheti, Saurabh , Nguyen, Thuy , Yepez‐Sisalema, Geovanna, Mitchell, Adriana O., Oatman, Stephanie R., Wang, Xue , Carrasquillo, Minerva M. , Beach, Thomas G., Golde, Todd E. , Haroutunian, Vahram , Jager, Philip L. De , Bennett, David A. , Seyfried, Nicholas T. , Ertekin‐Taner, Nilüfer , Initiative, Accelerating Medicines Partnership for Alzheimer’s Disease (AMP‐AD) Diversity, Heath, Laura , Johnson, Ryan, Wang, Erming , Ma, Yiyi , Lopes, Kátia de Paiva , Wang, Xue, Carrasquillo, Minerva M. , Runnels, Alexi , Teich, Andrew F. , Beach, Thomas G. , Serrano, Geidy E. , Barnes, Lisa L. , Wang, Minghui , Zhang, Bin , Greenwood, Anna, Initiative, Accelerating Medicines Partnership for Alzheimer’s Disease (AMP‐AD) Diversity

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.090590 Get It

AbstractBackgroundAlzheimer’s disease (AD) is a devastating neurodegenerative disorder with few therapies to treat, mitigate or prevent its onset. Understanding of this disease is predominantly based on research in non‐Hispanic Whites (NHW) although AD disproportionately affects African Americans (AA) and Latin Americans (LA), underrepresented in AD research. To address this knowledge gap, the Accelerating Medicine Partnership for Alzheimer’s Disease (AMP‐AD) Diversity Working Group was launched to generate multi‐omics data from post‐mortem brain tissue from donors of predominantly AA and LA descent. Here, we focus on genomic and transcriptomics measures, made available through the AD Knowledge Portal (ADKP).MethodBrain tissue from dorsolateral prefrontal cortex (DLPFC), caudate nucleus (CN), superior temporal gyrus (STG) and temporal pole (TP) regions of AA (N = 299), LA (N = 344) and NHW (N = 532) donors was obtained through Mayo Clinic, Mt. Sinai School of Medicine, Emory, Columbia, Rush Alzheimer’s Disease Center, Banner Sun Health, and 1Florida. DNA extracted from DLPFC tissue samples (n = 641) was utilized for whole genome sequencing (WGS) at New York Genome Center (NYGC). RNAseq of 2,224 samples was conducted either at Mayo, Rush or NYGC. Sequencing reads were processed through GenomeGPS and MAPRseq pipelines for WGS and RNAseq data, respectively. Following quality control (QC), RNAseq data was normalized and assessed for sources of variation (SOV). Integration of WGS and RNAseq data to perform comparative eQTL analysis across multi‐ethnic populations and brain regions is ongoing.ResultWGS data for 621 donors, and RNAseq data generated at Mayo (n = 1,136 samples), Rush (n = 627), and NYGC (n = 779) sequencing centers, were deposited to the ADKP. Consensus processing of RNAseq data revealed site, sex, race/ethnicity, RIN, AD diagnosis, age at death and/or library batch as SOV across various sites and brain regions. Principal component analysis of gene expression measures revealed no major stratification by disease or brain region. Accompanying clinical metadata of donors have been distributed through ADKP.ConclusionThese multi‐omics data made available to the research community is expected to be an initial step towards bridging our data and knowledge gap to elucidate conserved and distinct AD related pathways across these underrepresented at‐risk populations.
Multimodal Genetic Analysis of Brain Amyloidosis
Wu, Yiyang , Mormino, Elizabeth C. , Jager, Philip L. De , Mayeux, Richard, Kunkle, Brian W. , Schellenberg, Gerard D., Huentelman, Matthew J. , Hamilton‐Nelson, Kara L. , Pericak‐Vance, Margaret A., Haines, Jonathan L. , Montine, Thomas J. , Beecham, Gary W. , Wang, Ting‐Chen , Archer, Derek B. , Ali, Muhammad , Buckley, Rachel F. , Lee, Annie , Saykin, Andrew J. , Schneider, Julie A. , Bennett, David , Barnes, Lisa L. , Vardarajan, Badri Narayan , Mayeux, Richard , Bush, William S. , Keene, C. Dirk , Seshadri, Sudha , Sperling, Reisa Anne , Vemuri, Prashanthi , Ramanan, Vijay K. , Goate, Alison , Cruchaga, Carlos , Hohman, Timothy J. , Dumitrescu, Logan

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.090566 Get It

AbstractBackgroundGenome‐wide association studies (GWAS) in Alzheimer’s disease (AD) leveraging endophenotypes beyond case/control diagnosis, such as brain amyloid β pathology, have shown promise in identifying novel variants and understanding their potential functional impact. In this study, we leverage two brain amyloid β pathology measurement modalities, PET imaging and neuropathology, to address sample size limitations and to discover novel genetic drivers of disease.MethodWe conducted a meta‐analysis on an amyloid PET imaging GWAS (N = 7,036, 35% amyloid positive, 53.67% female, age = 71) and an autopsy GWAS of brain amyloidosis (N = 6,519, 63.08% amyloid positive, 51.34% female, age at death = 83), both adjusted for covariates including age, sex and principal components of genetic ancestry. All participants in both GWAS were unrelated individuals of European descent. We defined amyloid positivity as moderate or frequent neuritic plaques using the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) staging scores within each autopsy cohort. A Gaussian mixture model (GMM) was applied to each amyloid PET imaging cohort to identify the cohort and tracer‐specific cut‐offs that differentiate amyloid positive and negative populations.ResultThe genome‐wide significant results from the meta‐analysis identified three known AD loci (APOE, CR1, and BIN1) and a novel chromosome 17 locus (rs35635959, intergenic, MAF = 0.27, OR = 1.18, p = 1.47 × 10‐8). The MAGMA gene‐level analysis excluding the APOE region suggests significant associations between rs35635959 and COASY, PLEKHH3, and TUBG2 on chromosome 17, implying the potential roles of these genes on amyloidosis. Functional annotations of rs35635959 leveraging brain eQTL databases indicate its association with differential gene expression of COASY and TUBG2 in AD brains. ROSMAP bulk and single‐nucleus RNAseq analyses link TUBG2 downregulation to the higher amyloid burden and AD diagnosis while suggesting such observations are enriched in excitatory and inhibitory neurons, reaching FDR significance.ConclusionThis study is the most extensive European GWAS of brain amyloidosis, and our findings replicate known AD loci and identify a possible novel locus (index SNP rs35635959) on chromosome 17. Functional annotations of the novel variant indicate TUBG2, implicating in microtubule organization, warrants further assessment. Ongoing efforts aim to validate these novel effects using independent datasets.
Rare genetic variation in fibronectin 1 (FN1) protects against APOE ɛ4 in Alzheimer’s Disease
Uzrek, Bengisu Turgutalp, Reyes‐Dumeyer, Dolly , Jülich, Dörthe , Tayran, Hüseyin, Lantigua, Rafael , Medrano, Martin , Mejía, Diones Rivera , Recio, Patricia, Flaherty, Delaney, Nuriel, Tal , Ertekin‐Taner, Nilüfer , Holley, Scott A. , Mayeux, Richard , Bhattarai, Prabesh , Gunasekaran, Tamil Iniyan , Lee, Annie , Yılmaz, Elanur , Dalgard, Clifton L. , Dickson, Dennis W. , Teich, Andrew F. , Kizil, Caghan , Vardarajan, Badri Narayan

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.089111 Get It

AbstractBackgroundAPOEε4 significantly increases the risk of developing Alzheimer’s disease (AD). Cognitively healthy APOEε4‐carriers exist, suggesting potential protective mechanisms against APOEε4. We hypothesized that some APOEε4‐carriers may have genetic variations protecting them from developing APOEε4‐mediated AD pathology. We aim to identify these protective genetic variants.MethodsWhole genome sequencing (WGS) and cerebrospinal fluid (CSF) proteomics were performed from human cohorts to identify potential protective variants segregating exclusively among APOEε4 carriers. Bioinformatic analyses were performed to select candidate target genes. Immunohistochemistry on postmortem human brain tissues and mouse models expressing human APOE variants were performed along with in‐vivo functional studies in adult zebrafish AD model.ResultWGS analyses revealed 510 potential gene variants segregating exclusively among APOEε4 carriers, which included rare and loss‐of‐function (LOF) variants. Pathway analysis of these genes showed significant enrichment in extracellular matrix (ECM)‐related processes, suggesting protective effects of LOF in ECM proteins. This was further validated by CSF proteome profiling and subsequent analyses in APOEε4 carriers and non‐carriers. Fibronectin‐1 (FN1) and Collagen‐6A2 (COL6A2) were prioritized as candidate target genes for postmortem validation and in‐vivo functional studies. FN1 protein was increased in APOEε4 carriers resulting in thickened ECM at the basement membrane around the blood vessels, potentially impairing pathology‐induced responses such as clearance and immune system activity. This observation is validated in human brains, mouse models and zebrafish model; therefore, the pathological association of FN1 to AD is evolutionarily conserved. Supporting this hypothesis, in‐vivo functional study in zebrafish model with LOF mutations in fn1b revealed that fibronectin LOF enhanced gliovascular remodeling and microglial activation while reducing astrogliosis, suggesting that pathological accumulation of FN1 could impair toxic protein clearance, which is ameliorated with FN1 LOF.ConclusionThe vascular deposition of the ECM components FN1 and COL6A2 are increased in APOEε4 carriers. Rare variant in FN1 protect against APOEε4‐mediated pathogenesis in AD. We propose a new disease mechanisms and potential therapeutic intervention targets for vascular contribution to dementia to mitigate the risk of developing AD.
A multiethnic transcriptome for Alzheimer Disease identifies cross‐ancestry and ancestry‐specific expression profiles
Yang, Zikun , Cieza, Basilio, Reyes‐Dumeyer, Dolly , Jin, Lee‐Way , Pericak‐Vance, Margaret A, Mayeux, Richard , Lee, Annie , Dugger, Brittany N. , Murray, Melissa E. , Dickson, Dennis W. , Vance, Jeffery M. , Foroud, Tatiana , Teich, Andrew F. , Tosto, Giuseppe

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.092011 Get It

AbstractBackgroundAlzheimer’s Disease (AD) presents complex molecular heterogeneity, influenced by a variety of factors including heterogeneous phenotypic, genetic, and neuropathologic presentations. Regulation of gene expression mechanisms is a primary interest of investigations aiming to uncover the underlying disease mechanisms and progression.MethodWe generated bulk RNA‐sequencing in prefrontal cortex from 565 AD brain samples (non‐Hispanic Whites, n = 399; Hispanics, n = 113; African American, n = 12) across six U.S. brain banks, and conducted differential gene expression and enrichment analyses. We sought to identify cross‐ancestry and ancestry‐specific differentially expressed genes (DEG) and pathways across Braak stages, adjusting for sex, age at death, and RNA quality metrics. We validated our findings using the Religious Orders Study/Memory and Aging Project study (ROS/MAP, n = 1,095). Lastly, we validated top DEG using publically‐available human single‐nucleus RNA sequencing (snRNAseq) data.ResultAD‐known genes VGF (LFC = ‐0.661, padj = 3.78) and ADAMTS2 (padj = 1.21) were consistently differentially expressed across statistical models, ethnic groups, and replicated in ROS/MAP (Figure 1). Genes from the heat shock protein (HSP) family, e.g. HSPB7 (padj = 3.78), were the top DEG, also replicated in ROS/MAP. Ethnic‐stratified analyses prioritized TNFSF14 and SPOCD1 as top DEG in Hispanic samples. Gene set enrichment analysis highlighted several significantly pathways, including “TYROBP causal network in microglia” (WP3945; padj = 1.68) and “Alzheimer Disease” (WP5124; padj = 4.24). snRNAseq validated several DEG, including VGF downregulated in neurons (padj = 1.1).ConclusionTo our knowledge, this is the largest diverse transcriptome study for AD in post‐mortem tissue. We identified perturbated genes and pathways resulting in cross‐ethnic and ethnic‐specific findings, ultimately highlighting the importance of diversity in AD investigations.